Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 75 years old, of any gender
• People who have been diagnosed (confirmed by tissue testing) with certain types of B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma, primary mediastinal B-cell lymphoma, mantle cell lymphoma (MCL), or other similar types that have converted from a slower-growing form
• People whose lymphoma has come back or stopped responding to treatment — the specific requirements depend on the type of lymphoma (confirm with trial site for your specific situation)
• People whose previous treatment included a type of drug called a CD20 antibody (unless their cancer cells do not carry the CD20 marker) and a type of chemotherapy called anthracyclines
• People who have at least one area of disease that can be measured on a scan, with the largest spot being at least 1.5 cm across
• People with an expected survival of at least 12 weeks
• People whose tumour tissue tests positive for a marker called CD19
• People with a general health/activity score of 0–2 on a standard medical scale (meaning able to carry out daily activities, with at most some limitations)
• People whose liver, kidney, and heart are functioning well enough to meet specific laboratory test thresholds (confirm details with trial site)
• People whose resting blood oxygen level is above 92% in normal indoor air
• People who have previously had a stem cell transplant
• People who have finished other anti-lymphoma treatments (such as chemotherapy, radiotherapy, or immunotherapy) at least 3 weeks before starting this trial
• People who previously received CAR-T cell therapy but whose treatment failed or whose disease came back at least 3 months after that therapy was assessed
• Women of childbearing age who have a negative pregnancy test and agree to use effective contraception during the trial
• People who have tested negative for COVID-19 and swine flu on two separate tests

Who may not be able to join:

• People who are allergic to any ingredient in the cell therapy product used in this trial
• People who have a history of any other cancer
• People who have had, or are currently being treated for, a serious immune reaction called graft-versus-host disease (GvHD) — specifically moderate to severe forms (Grade II–IV)
• People who received gene therapy within the past 3 months
• People who have an active infection currently requiring treatment (minor infections like simple urinary tract infections or bacterial throat infections may be acceptable — confirm with trial site)
• People who are infected with hepatitis B, hepatitis C, syphilis, HIV, or other conditions that weaken the immune system (some hepatitis B cases may still be considered — confirm with trial site)
• People with serious heart problems classified as Grade III or IV by a standard medical heart-function scale
• People who still have significant side effects from previous cancer treatment that have not recovered to a mild level (with the exception of tiredness, loss of appetite, or hair loss)
• People with a history of epilepsy or other conditions affecting the brain or nervous system
• People whose brain scans show signs that the lymphoma has spread to the central nervous system
• Women who are currently breastfeeding and unwilling to stop
• People who have any other condition or factor that the trial doctor believes could increase risk or affect the trial results

Important: Always verify eligibility with the trial site directly before applying.